Expression of mos in ependymal gliomas
Expression of mos in ependymal gliomas
复制标题
DOI：
10.1309/dl2tldjg7jb1bq72
复制
发表时间：
2003-11-01
影响因子：
3.5
通讯作者：
Love, S
中科院分区：
文献类型：
--
作者：
Athanasiou, A;Perunovic, B;Love, S
已知c-mos基因及其蛋白产物mos（有丝分裂原活化蛋白激酶转导途径的组成部分）参与减数分裂和有丝分裂的控制。除了我们以前对肺癌和星形胶质细胞瘤的研究外，很少有关于其在人类肿瘤形成中的作用的报道。本研究旨在探讨mos在室管膜肿瘤中的表达及其与肿瘤分级、增殖分数和临床行为的关系，我们研究了34例室管膜瘤活检标本中mos的表达。16例（47%）mos胞浆内免疫阳性，与肿瘤分级显著相关：21例II级室管膜瘤中5例（24%）; 13例III级间变性室管膜瘤中11例（85%）（P <0.01）。MIB-1标记指数大于4%的肿瘤比增殖分数较低的肿瘤更可能是mos免疫阳性（P = 0.012）。mos的过度表达与无复发间隔呈显著负相关（P = 0.05），但与总生存率无关。我们的研究结果表明，mos的过度表达确定了室管膜肿瘤的生物学侵袭性亚组，并可能参与其肿瘤进展。
The c-mos gene and its protein product mos, components of the mitogen-activated protein kinase transduction pathway, are known to be involved in the control of meiosis and mitosis. Apart from our previous studies on lung carcinomas and astrocytic gliomas, little has been published about its role in human neoplasia. The aim of this study was to investigate the expression of mos in ependymal neoplasms and to correlate it with tumor grade, proliferative fraction, and clinical behavior.We studied mos expression in biopsy specimens from 34 patients with ependymomas. Intracytoplasmic immunopositivity for mos was found in 16 (47%) and was associated significantly with tumor grade: 5 (24%) of 21 grade II ependymomas; 11 (85%) of 13 grade III anaplastic ependymomas (P < .01). Tumors with an MIB-1 labeling index of more than 4% were significantly more likely than those with a lower proliferative fraction to be immunopositive for mos (P = .012). Eypression of mos showed a significant negative association with recurrence-free interval (P = .05) but not with overall survival.Our results suggest that overexpression of mos identifies a biologically aggressive subgroup of ependymal tumors and may be involved in their neoplastic progression.